Published in J Immunol on March 01, 1988
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol (1994) 2.68
Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor. Mol Cell Biol (1996) 2.64
Replication of wild-type and mutant human cytomegalovirus in life-extended human diploid fibroblasts. J Virol (2000) 2.41
Human cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow. J Virol (1994) 2.31
Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol (1997) 2.21
Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol (1991) 2.07
Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol (2001) 1.65
Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest (1997) 1.62
Multiple regulatory events influence human cytomegalovirus DNA polymerase (UL54) expression during viral infection. J Virol (1996) 1.60
Human cytomegalovirus gene expression is silenced by Daxx-mediated intrinsic immune defense in model latent infections established in vitro. J Virol (2007) 1.60
Effect of a modulator deletion on transcription of the human cytomegalovirus major immediate-early genes in infected undifferentiated and differentiated cells. J Virol (1997) 1.48
An immortalized human fibroblast cell line is permissive for human cytomegalovirus infection. J Virol (1993) 1.46
Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus. J Clin Invest (1990) 1.46
Phosphorylation of the human cytomegalovirus 86-kilodalton immediate-early protein IE2. J Virol (1998) 1.45
Extracellular signal-regulated kinase activity is sustained early during human cytomegalovirus infection. J Virol (1998) 1.41
Cellular and viral control over the initial events of human cytomegalovirus experimental latency in CD34+ cells. J Virol (2010) 1.29
Human cytomegalovirus infection inhibits tumor necrosis factor alpha (TNF-alpha) signaling by targeting the 55-kilodalton TNF-alpha receptor. J Virol (2003) 1.28
Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J Virol (1999) 1.23
Repression by a differentiation-specific factor of the human cytomegalovirus enhancer. Nucleic Acids Res (1996) 1.21
Human cytomegalovirus chemokine receptor gene US28 is transcribed in latently infected THP-1 monocytes. J Virol (2001) 1.18
An endoplasmic reticulum protein, p180, is highly expressed in human cytomegalovirus-permissive cells and interacts with the tegument protein encoded by UL48. J Virol (2002) 1.14
Rabies virus replication in primary murine bone marrow macrophages and in human and murine macrophage-like cell lines: implications for viral persistence. J Virol (1995) 1.13
A myeloid progenitor cell line capable of supporting human cytomegalovirus latency and reactivation, resulting in infectious progeny. J Virol (2012) 1.07
Isolation and characterization of a low-abundance splice variant from the human cytomegalovirus major immediate-early gene region. J Virol (1995) 1.05
Host microRNA regulation of human cytomegalovirus immediate early protein translation promotes viral latency. J Virol (2014) 1.04
Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells. Proc Natl Acad Sci U S A (2011) 1.03
The human cytomegalovirus UL36 gene controls caspase-dependent and -independent cell death programs activated by infection of monocytes differentiating to macrophages. J Virol (2010) 0.97
Aleutian mink disease parvovirus infection of mink peritoneal macrophages and human macrophage cell lines. J Virol (1993) 0.96
Latent Kaposi's sarcoma-associated herpesvirus infection of monocytes downregulates expression of adaptive immune response costimulatory receptors and proinflammatory cytokines. J Virol (2012) 0.95
The role of ATF in regulating the human cytomegalovirus DNA polymerase (UL54) promoter during viral infection. J Virol (1997) 0.92
Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1. J Virol (2002) 0.91
Characterization of Pichinde virus infection of cells of the monocytic lineage. J Virol (1991) 0.90
Contribution of the Major ND10 Proteins PML, hDaxx and Sp100 to the Regulation of Human Cytomegalovirus Latency and Lytic Replication in the Monocytic Cell Line THP-1. Viruses (2015) 0.87
Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J Clin Invest (1996) 0.87
The intimate relationship between human cytomegalovirus and the dendritic cell lineage. Front Microbiol (2014) 0.85
Cyclophilin A is required for efficient human cytomegalovirus DNA replication and reactivation. J Gen Virol (2012) 0.85
Nuclear localization of tegument-delivered pp71 in human cytomegalovirus-infected cells is facilitated by one or more factors present in terminally differentiated fibroblasts. J Virol (2010) 0.84
Comprehensive analysis of human cytomegalovirus microRNA expression during lytic and quiescent infection. PLoS One (2014) 0.82
Cellular defense against latent colonization foiled by human cytomegalovirus UL138 protein. Sci Adv (2015) 0.81
Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients. J Gen Virol (2014) 0.80
Analysis of human cytomegalovirus replication in primary cultured human corneal endothelial cells. Br J Ophthalmol (2015) 0.78
The human cytomegalovirus lytic cycle is induced by 1,25-dihydroxyvitamin D3 in peripheral blood monocytes and in the THP-1 monocytic cell line. Virology (2015) 0.76
Macrophages and the Viral Dissemination Super Highway. EC Microbiol (2016) 0.75
Epigenetically repressing human cytomegalovirus lytic infection and reactivation from latency in THP-1 model by targeting H3K9 and H3K27 histone demethylases. PLoS One (2017) 0.75
Human cytomegalovirus reactivation from latency: validation of a "switch" model in vitro. Virol J (2016) 0.75
Enhanced cytomegalovirus infection in human trabecular meshwork cells and its implication in glaucoma pathogenesis. Sci Rep (2017) 0.75
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain (1989) 5.59
Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci U S A (1984) 4.56
Cytomegalovirus and Rasmussen's encephalitis. Lancet (1990) 2.96
The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain (1989) 2.59
The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain (1991) 2.11
Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology (1978) 2.09
Viruses disrupt functions of human lymphocytes. Effects of measles virus and influenza virus on lymphocyte-mediated killing and antibody production. J Exp Med (1984) 1.92
The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain (1999) 1.91
The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology (1998) 1.58
A population-based study of multiple sclerosis in twins: update. Ann Neurol (1993) 1.46
HTLV-1 associated myelopathy in Canada. Can J Neurol Sci (1989) 1.40
Systemic alpha-interferon therapy of multiple sclerosis. Neurology (1984) 1.35
The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain (1991) 1.25
A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology (1984) 1.24
Wnt signaling regulates the function of MyoD and myogenin. J Biol Chem (2000) 1.22
Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis (1986) 1.22
Disease activity markers in multiple sclerosis. Another look at suppressor cells defined by monoclonal antibodies OKT4, OKT5, and OKT8. J Neuroimmunol (1984) 1.18
Cytomegalovirus infection of peripheral blood mononuclear cells: effects on interleukin-1 and -2 production and responsiveness. J Virol (1988) 1.13
Myocyte enhancer factor 2C and Nkx2-5 up-regulate each other's expression and initiate cardiomyogenesis in P19 cells. J Biol Chem (1998) 1.12
Cytomegalovirus in the brain: in vitro infection of human brain-derived cells. J Infect Dis (1990) 1.10
The extent of human cytomegalovirus replication in primary neurons is dependent on host cell differentiation. J Infect Dis (1994) 1.10
The prevalence of primary Sjögren's syndrome in a multiple sclerosis population. Ann Neurol (1989) 1.10
The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis. Brain (2000) 1.10
Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs. Am J Vet Res (1996) 1.09
A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology (1992) 1.05
Biogenesis of poxviruses: role for the DNA-dependent RNA polymerase II of the host during expression of late functions. Proc Natl Acad Sci U S A (1979) 1.05
HIV-1 infection of human brain-derived microvascular endothelial cells in vitro. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.04
Myocyte enhancer factor 2C and myogenin up-regulate each other's expression and induce the development of skeletal muscle in P19 cells. J Biol Chem (2000) 1.03
Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol (1992) 0.99
Role of the monocyte in cytomegalovirus-mediated immunosuppression in vitro. J Infect Dis (1986) 0.98
Identification of antigenic determinants by polyclonal and hybridoma antibodies induced during the course of infection by vaccinia virus. Virology (1986) 0.98
Variation in immunoglobulin G and albumin concentrations during lumbar CSF removal: a reappraisal. Neurology (1982) 0.98
Nkx2-5 activity is essential for cardiomyogenesis. J Biol Chem (2001) 0.97
A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope. Virology (1991) 0.97
A new solid-phase enzyme-linked immunosorbent assay for specific antibodies to measles virus. J Infect Dis (1983) 0.95
Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol (1989) 0.91
Refined localisation of the genes for nebulin and titin on chromosome 2q allows the assignment of nebulin as a candidate gene for autosomal recessive nemaline myopathy. Eur J Hum Genet (1998) 0.90
The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci (2000) 0.89
Some clinical and pathologic observations on chronic myelopathy: a variant of multiple sclerosis. J Neurol Neurosurg Psychiatry (1990) 0.88
Factors in serum regulate muscle development in P19 cells. In Vitro Cell Dev Biol Anim (1999) 0.87
Extramedullary hematopoiesis and spinal cord compression complicating polycythemia rubra vera. Ann Neurol (1980) 0.87
Cerebellar astrocytoma with benign histology and malignant clinical course. Case report. J Neurosurg (1981) 0.86
Mollaret's meningitis associated with herpes simplex type 2 infection. Neurology (1993) 0.86
Myocyte enhancer factor 2C upregulates MASH-1 expression and induces neurogenesis in P19 cells. FEBS Lett (2000) 0.85
Hyperbaric oxygen therapy in chronic stable multiple sclerosis: double-blind study. Neurology (1986) 0.85
An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology (1993) 0.84
Myopathy in primary systemic amyloidosis. Can J Neurol Sci (1988) 0.84
Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci (1988) 0.84
Absence of antibody to HTLV I and III in sera of Canadian patients with multiple sclerosis and chronic myelopathy. Ann Neurol (1986) 0.84
Natural killer cell activity in patients with multiple sclerosis given alpha interferon. Ann Neurol (1983) 0.83
Influence of RNA polymerase II upon vaccinia virus-related translation examined by means of alpha-amanitin. Virus Res (1986) 0.83
Selective spinal cordectomy: clinicopathological correlation. J Neurosurg (1982) 0.83
Diagnostic brain MRI findings in primary progressive multiple sclerosis. Mult Scler (2000) 0.82
Butyrycholinesterase K variant and Alzheimer's disease. J Neurol (1999) 0.81
Recurrent cerebral embolism in cardiac amyloidosis. Neurology (1981) 0.81
Similarities of guamanian ALS/PD to post-encephalitic parkinsonism/ALS: possible viral cause. Can J Neurol Sci (1990) 0.81
Ondansetron for intractable vertigo complicating acute brainstem disorders. Lancet (1995) 0.81
An open trial of OKT3 in patients with multiple sclerosis. Neurology (1991) 0.80
Nucleotide sequence analysis of an HTLV-I isolate from a Chilean patient with HAM/TSP. AIDS Res Hum Retroviruses (1992) 0.80
Interpretation of single band patterns in CSF protein electrophoresis. Can J Neurol Sci (1988) 0.79
Retroviruses and multiple sclerosis. I. Analysis of seroreactivity by western blot and radioimmune assay. Neurology (1990) 0.79
Evidence for a prolonged role of alpha 4 integrin throughout active experimental allergic encephalomyelitis. Neurology (1996) 0.79
Factors in serum regulate Nkx2.5 and MEF2C function. In Vitro Cell Dev Biol Anim (2002) 0.78
"Sporadic" motoneuron disease due to familial SOD1 mutation with low penetrance. Lancet (1995) 0.78
A monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. J Magn Reson Imaging (1996) 0.78
Human T-lymphotropic virus type 1 in coastal natives of British Columbia: phylogenetic affinities and possible origins. J Virol (1995) 0.78
Cytomegalovirus-caused release of collagenase IV from human cerebral microvascular endothelial cells. Clin Diagn Virol (1995) 0.78
Familial stroke syndrome associated with mitral valve prolapse. Ann Neurol (1980) 0.78
Trichlorethylene poisoning mimicking multiple sclerosis. Can J Neurol Sci (1988) 0.78
A polymerase chain reaction screening strategy for the promoter of the canine dystrophin gene. Am J Vet Res (1999) 0.77
Hand wasting due to mid-cervical spinal cord compression. Can J Neurol Sci (1987) 0.77
The failure of monoclonal antibody-defined lymphocyte subsets to monitor disease activity in patients with multiple sclerosis. Ann N Y Acad Sci (1984) 0.77
Immune balance in the cytomegalovirus-infected host: in vitro studies of virus-lymphocyte interactions and the effects on specific lymphocyte function. Birth Defects Orig Artic Ser (1984) 0.77
HTLV-I infection associated with disease in aboriginal Indians from British Columbia: a serological and PCR analysis. Clin Diagn Virol (1994) 0.77
New developments with herpesviruses and the nervous system. Curr Opin Neurol Neurosurg (1993) 0.76
Encephalopathy in liver transplantation: neuropathology and CMV infection. Can J Neurol Sci (1990) 0.76
Comparative analysis of the antibody response to the HTLV-I gag and env proteins in HTLV-I asymptomatic carriers and HAM/TSP patients: an isotype and subclass analysis. Scand J Immunol (1994) 0.76
MR imaging field strength: prospective evaluation of the diagnostic accuracy of MR for diagnosis of multiple sclerosis at 0.5 and 1.5 T. Radiology (1995) 0.75
Retroviruses and multiple sclerosis. II. Failure of gene amplification techniques to detect viral sequences unique to the disease. Neurology (1990) 0.75
Anticytokine antibodies in beta-interferon-treated patients. Neurology (1998) 0.75
The variability of manual and computer assisted quantification of multiple sclerosis lesion volumes. Med Phys (1996) 0.75
Pathological and molecular biological features of a myelopathy associated with HTLV-1 infection. Can J Neurol Sci (1991) 0.75
Tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci (1989) 0.75
Quantification of multiple sclerosis lesion volumes in 1.5 and 0.5 T anisotropically filtered and unfiltered MR exams. Med Phys (1996) 0.75
Mitral valve prolapse: a cause of stroke in children? Dev Med Child Neurol (1981) 0.75
Freedom of access to information and the right of privacy. Image (IN) (1976) 0.75
Possible patterns & systems of antenatal care. Personally held case notes. Midwives Chron (1983) 0.75
Spongiform encephalopathy of long duration: a family study. Can J Neurol Sci (1980) 0.75
Absence of HTLV-I and HTLV-II proviral genome in the brains of patients with multiple sclerosis and amyotrophic lateral sclerosis. Can J Neurol Sci (1992) 0.75
Preparative isoelectric focusing in agarose. J Immunol Methods (1980) 0.75
Immunological complications in multiple sclerosis patients receiving interferon. Ann Neurol (1985) 0.75
Clinical trial of natural alpha interferon in multiple sclerosis. Ann N Y Acad Sci (1984) 0.75